Physical activity, health-related quality of life, and adjuvant endocrine therapy-related symptoms in women with hormone receptor-positive breast cancer.
Adult
Black or African American
/ genetics
Aged
Antineoplastic Agents, Hormonal
/ therapeutic use
Aromatase Inhibitors
/ adverse effects
Body Mass Index
Breast Neoplasms
/ drug therapy
Chemotherapy, Adjuvant
/ adverse effects
Combined Modality Therapy
Exercise
Female
Hormones
/ genetics
Humans
Medication Adherence
Middle Aged
Quality of Life
Tamoxifen
/ adverse effects
White People
/ genetics
breast neoplasms
exercise
quality of life
therapeutics
Journal
Cancer
ISSN: 1097-0142
Titre abrégé: Cancer
Pays: United States
ID NLM: 0374236
Informations de publication
Date de publication:
01 09 2020
01 09 2020
Historique:
received:
03
06
2019
revised:
03
06
2020
accepted:
03
06
2020
pubmed:
3
7
2020
medline:
22
5
2021
entrez:
3
7
2020
Statut:
ppublish
Résumé
Physical activity (PA) is recommended for women with breast cancer (BC); however, data are sparse on the association of PA with quality of life (QOL) and patient-reported symptoms for women on adjuvant endocrine therapy (AET). Women with hormone receptor-positive BC who were taking AET completed standardized surveys about their health-related QOL, AET-related symptoms, and levels of PA using validated measures. A Wald chi-square test and an analysis of variance were used to assess associations with PA and independent variables. Generalized linear regression analyses assessed associations between PA, QOL, and AET-related symptoms. The analytic cohort included 485 Black and White women. Black race, a high body mass index (BMI), and being on aromatase inhibitors (vs tamoxifen) were associated with lower PA in a bivariate analysis. In a multivariate analysis, lower self-reported PA was associated with a high BMI (P = .02) and chemotherapy uptake (P = .006). Better health-related QOL (P = .01), less severe overall AET-related symptoms (P = .02), and less severe gynecological symptoms (P = .03) were associated with increasing levels of moderate PA. Among women taking AET, moderate levels of PA may be associated with fewer medication-related symptoms and overall better ratings of health-related QOL. Because of the low levels of PA observed in the sample overall and particularly for Black women, identifying successful strategies to promote PA are needed.
Sections du résumé
BACKGROUND
Physical activity (PA) is recommended for women with breast cancer (BC); however, data are sparse on the association of PA with quality of life (QOL) and patient-reported symptoms for women on adjuvant endocrine therapy (AET).
METHODS
Women with hormone receptor-positive BC who were taking AET completed standardized surveys about their health-related QOL, AET-related symptoms, and levels of PA using validated measures. A Wald chi-square test and an analysis of variance were used to assess associations with PA and independent variables. Generalized linear regression analyses assessed associations between PA, QOL, and AET-related symptoms.
RESULTS
The analytic cohort included 485 Black and White women. Black race, a high body mass index (BMI), and being on aromatase inhibitors (vs tamoxifen) were associated with lower PA in a bivariate analysis. In a multivariate analysis, lower self-reported PA was associated with a high BMI (P = .02) and chemotherapy uptake (P = .006). Better health-related QOL (P = .01), less severe overall AET-related symptoms (P = .02), and less severe gynecological symptoms (P = .03) were associated with increasing levels of moderate PA.
CONCLUSIONS
Among women taking AET, moderate levels of PA may be associated with fewer medication-related symptoms and overall better ratings of health-related QOL. Because of the low levels of PA observed in the sample overall and particularly for Black women, identifying successful strategies to promote PA are needed.
Identifiants
pubmed: 32614992
doi: 10.1002/cncr.33054
pmc: PMC8018708
mid: NIHMS1615954
doi:
Substances chimiques
Antineoplastic Agents, Hormonal
0
Aromatase Inhibitors
0
Hormones
0
Tamoxifen
094ZI81Y45
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
4059-4066Subventions
Organisme : NCATS NIH HHS
ID : UL1 TR002649
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA093423
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA154848
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA016059
Pays : United States
Informations de copyright
© 2020 American Cancer Society.
Références
Oncol Nurs Forum. 2013 Sep;40(5):472-80
pubmed: 23989021
J Natl Cancer Inst. 2011 Sep 7;103(17):1299-309
pubmed: 21743022
Health Promot Pract. 2020 Mar;21(2):268-276
pubmed: 30203677
J Nurs Scholarsh. 2019 May;51(3):317-325
pubmed: 30874369
JAMA. 2003 Sep 10;290(10):1331-6
pubmed: 12966124
Compr Physiol. 2018 Dec 13;9(1):165-205
pubmed: 30549018
Psychooncology. 2013 Apr;22(4):783-91
pubmed: 22451113
Int J Behav Nutr Phys Act. 2007 Feb 17;4:4
pubmed: 17306031
CA Cancer J Clin. 2012 Jul-Aug;62(4):275-6
pubmed: 22570061
Cancer Causes Control. 2018 May;29(4-5):475-484
pubmed: 29511931
CA Cancer J Clin. 2015 Mar;65(2):87-108
pubmed: 25651787
CA Cancer J Clin. 2012 Jan-Feb;62(1):30-67
pubmed: 22237782
Support Care Cancer. 2019 Dec;27(12):4745-4752
pubmed: 30972643
Health Educ Behav. 2006 Oct;33(5):604-24
pubmed: 16923833
JAMA Oncol. 2019 May 1;5(5):710-714
pubmed: 30920602
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
J Cancer Surviv. 2013 Dec;7(4):563-9
pubmed: 23793468
Lancet. 2005 May 14-20;365(9472):1687-717
pubmed: 15894097
Breast Cancer Res Treat. 2015 Sep;153(2):253-61
pubmed: 26303657
Med Sci Sports Exerc. 2003 Aug;35(8):1381-95
pubmed: 12900694
Ann Oncol. 2017 Mar 1;28(3):487-496
pubmed: 27998966
Cancer Epidemiol Biomarkers Prev. 2013 Jun;22(6):1153-61
pubmed: 23576689
Int J Behav Nutr Phys Act. 2011 Oct 21;8:115
pubmed: 22018588
Int J Psychiatry Med. 2010;40(2):163-81
pubmed: 20848873
Soc Sci Med. 1991;32(6):705-14
pubmed: 2035047
J Cancer Surviv. 2016 Aug;10(4):654-62
pubmed: 26782031
J Clin Oncol. 2012 Nov 20;30(33):4124-33
pubmed: 23045575
J Cancer Surviv. 2018 Feb;12(1):74-81
pubmed: 29147853
Med Sci Sports Exerc. 2000 May;32(5):1018-23
pubmed: 10795795
J Clin Oncol. 1993 Mar;11(3):570-9
pubmed: 8445433
Disabil Rehabil. 2013;35(24):2038-45
pubmed: 23772995
Psychooncology. 2014 Nov;23(11):1314-7
pubmed: 24644092
In Vivo. 2019 May-Jun;33(3):881-888
pubmed: 31028212
Integr Cancer Ther. 2014 Mar;13(2):121-32
pubmed: 24105359
Cancer. 2019 Jul 1;125(13):2262-2271
pubmed: 30840336